皓宸医疗(002622) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥253,020,064.77, an increase of 20.48% year-over-year[2] - Net profit attributable to shareholders was ¥12,943,174.20, up 48.76% compared to the same period last year[2] - Net profit after deducting non-recurring gains and losses was ¥12,822,455.55, reflecting a 52.13% increase year-over-year[2] - Total operating revenue for Q3 2024 reached ¥635,030,298.87, an increase of 21.3% compared to ¥523,639,966.97 in the same period last year[20] - Operating profit for Q3 2024 was ¥31,450,295.28, down 8.0% from ¥34,527,160.94 in Q3 2023[21] - Net profit attributable to shareholders of the parent company was ¥13,496,659.38, a decrease of 17.4% from ¥16,321,536.90 in the previous year[22] - The company reported a decrease in comprehensive income attributable to shareholders of the parent company to ¥30,221,773.21 from ¥37,234,881.52 in the previous year[22] - Basic earnings per share for Q3 2024 were ¥0.0161, compared to ¥0.0194 in Q3 2023[22] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,565,747,164.97, representing a 1.94% increase from the end of the previous year[2] - The total assets of the company as of the latest report amount to CNY 1,565,747,164.97, an increase from CNY 1,535,890,599.57 at the beginning of the period[18] - The company's current liabilities total CNY 893,347,731.93, slightly up from CNY 891,757,164.96 at the beginning of the period[18] - Total liabilities increased to ¥1,073,322,431.77 from ¥1,070,747,639.58 year-over-year[19] - Shareholders' equity attributable to the parent company increased to ¥447,820,785.37, a rise of 3.47% compared to the end of last year[2] - The company’s total equity increased to ¥492,424,733.20, compared to ¥465,142,959.99 in Q3 2023[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥43,066,291.87, down 5.89% compared to the previous year[2] - The company reported a net cash flow from operating activities of ¥43,066,291.87, slightly down from ¥45,761,050.12 in Q3 2023[23] - Net cash flow from investment activities was -7,246,655.63, a decrease from 8,465,505.96 in the previous period[24] - Cash inflow from financing activities amounted to 78,400,000.00, significantly up from 17,000,000.00 in the prior period[24] - Cash outflow from financing activities totaled 103,754,320.53, compared to 39,356,135.12 previously[24] - The net cash flow from financing activities was -25,354,320.53, slightly worse than -22,356,135.12 in the last period[24] - The ending balance of cash and cash equivalents was 152,382,007.24, up from 150,098,941.99 at the end of the previous period[24] - The net increase in cash and cash equivalents for the quarter was 10,465,350.70, down from 31,870,420.96 in the previous quarter[24] Research and Development - R&D expenses decreased by ¥5,090,000, a reduction of 47.70% year-over-year[5] - Research and development expenses for Q3 2024 were ¥5,583,042.65, down from ¥10,675,860.37 in the same period last year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 44,932[8] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of the shares[8] - The second-largest shareholder, Shaanxi International Trust Co., holds 3.84% of the shares[8] Legal and Regulatory Issues - The company has disclosed multiple legal proceedings related to asset management disputes, with updates provided on various dates throughout 2024[10] - The company has reported that some bank accounts have been frozen, with ongoing updates on the situation[12] - The company is actively communicating with the Shanghai Financial Court regarding the execution procedures related to a legal case[11] - The company is facing uncertainty regarding control changes, as a lawsuit has been filed against it, and the outcome is pending[16] Asset Management and Freezing Issues - The company’s assets have been frozen due to a loan dispute, with the equity of its wholly-owned subsidiary, Zhiyu Medical, frozen for an amount of CNY 50 million, lasting for 1,097 days[14] - The total frozen bank balance of the company and its subsidiaries is CNY 574,164.23, accounting for 0.13% of the latest audited net assets[14] - The company is actively negotiating with Zhejiang Zheshang Asset Management Co., Ltd. and Wenzhou Bank to resolve the asset and account freezing issues through extension, installment repayment, and financing replacement[14] - The company’s largest shareholder, Huayin Rifen, has sent a notice indicating that the Shanghai Pudong Development Bank Guangzhou Branch has become the sole trustee of a specific asset management plan[15] Investment Risks - The company emphasizes the importance of investors being aware of investment risks[11] Audit Status - The company has not undergone an audit for the third quarter report[24]